PCVX insider sale: 7,395 shares reported

PCVX reported a resale transaction.

Rhea-AI Filing Summary

PCVX reported a resale transaction. James Wassil sold 7,395 shares of Common Stock on 03/10/2026 for $435,438.31, as shown on the notice filed by UBS Financial Services, Inc. The filing also lists RSU vesting amounts of 783 and 1,467 shares with vest dates in 2025.

Key Figures

Shares sold: 7,395 shares Proceeds: $435,438.31 RSU vest (1): 783 shares +1 more

4 metrics

Shares sold 7,395 shares sale on 03/10/2026

Proceeds $435,438.31 amount reported for the 03/10/2026 sale

RSU vest (1) 783 shares vest date 02/28/2025

RSU vest (2) 1,467 shares vest date 03/02/2025

Key Terms

Form 144, RSU Vest, Issuer

3 terms

Form 144 regulatory

"144: Securities Sold During The Past 3 Months"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

RSU Vest financial

"Common | 02/28/2025 | RSU Vest | Issuer"

Issuer financial

"RSU Vest | Issuer | | | 783"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did PCVX disclose in the Form 144?

The Form 144 reports that James Wassil sold 7,395 shares of Common Stock on 03/10/2026. The filing shows a reported sale value of $435,438.31 and lists UBS Financial Services, Inc. as the filer.

Who filed the Form 144 for the PCVX transaction?

The filing was submitted by UBS Financial Services, Inc. of New York, shown as the broker/filing agent. It lists the seller as James Wassil with the transaction details included in the notice.

Were any equity awards noted in the PCVX filing?

Yes, the filing lists RSU vesting entries: 783 RSUs with a vest date of 02/28/2025 and 1,467 RSUs with a vest date of 03/02/2025. These vesting figures appear in the securities-to-be-sold section.

What was the dollar value reported for the PCVX sale?

The Form 144 indicates the sale proceeds totaled $435,438.31 for 7,395 shares sold on 03/10/2026. The filing ties the dollar amount directly to the reported transaction by the named seller.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 04:08 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001813798
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vaxcyte, Inc.
SEC File Number	001-39323
Address of Issuer	825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CALIFORNIA 94070
Phone	650-837-0111
Name of Person for Whose Account the Securities are To Be Sold	Wassil Jim
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	2250	130747.50	143920361	04/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/28/2025	RSU Vest	Issuer			783	02/28/2025	N/A
Common	03/02/2025	RSU Vest	Issuer			1467	03/02/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	03/10/2026	7395	435438.31

144: Remarks and Signature

Remarks
Date of Notice	04/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for James Wassil
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)